Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Available from: Tack CJ, Jacob S, Desouza C, et al
BI 456906 (survodutide), developed as a dual agonist for GLP-1 and glucagon receptors for the treatment of obesity and NASH, is structurally modified from glucagon [109]
Patient pathway summary Initial enquiry by phone, email or our online form Face-to-face consultation at our Baker Street clinic Clinical assessment with dermoscopy where indicated Biopsy of any lesion of concern, with histopathology result within 714 days Treatment plan agreed (excision, laser, topical, or onward referral) Treatment delivered at our Baker Street site under local anaesthetic Follow-up review at 12 weeks for suture removal where applicable Final review at 6 weeks to assess healing and scar maturation Realistic outcomes discussion Lip surgery has specific cosmetic and functional considerations that we cover at consultation: Some scarring is inevitable wherever the lip skin is incised
Access this article Similar content being viewed by others Data Availability Data will be available on request from corresponding author
Together, they aim to create what the company calls dual activation and dual amplification of GLP-1 at the cellular level
US$ 25.77
US$ 22.87
US$ 26.61
US$ 29.81
US$ 22.08
US$ 20.47
